New strategy aims to make targeted therapy work longer for colorectal cancer patients
NCT ID NCT04587128
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial tests whether giving anti-EGFR drugs (panitumumab or cetuximab) early in treatment can help patients with left-sided metastatic colorectal cancer respond again to these drugs later. About 34 participants will receive alternating cycles of targeted therapy and chemotherapy over up to 5 years. The goal is to see if this approach improves disease control and delays progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Panitumumab, Cetuximab, Irinotecan, FOLFIRI, Bevacizumab
- What this could lead to
- If successful, this strategy could help some patients with metastatic colorectal cancer get more benefit from anti-EGFR therapies by using them earlier in treatment.
- What could go wrong
- This is a small, early-phase trial with only 34 participants, so results may not apply broadly. The approach may not improve disease control or survival, and side effects from the drugs can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?